CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received an average recommendation of “Hold” from the twenty brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $73.31.

Several brokerages recently weighed in on CRSP. Stifel Nicolaus cut their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday. Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a research note on Tuesday. Oppenheimer decreased their target price on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Piper Sandler reiterated an “overweight” rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Citigroup lowered their target price on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 23rd.

Insider Buying and Selling

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently modified their holdings of CRSP. Capital International Investors boosted its holdings in shares of CRISPR Therapeutics by 27.8% in the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after acquiring an additional 1,702,624 shares during the period. SR One Capital Management LP purchased a new position in CRISPR Therapeutics during the 1st quarter worth $71,496,000. Norges Bank acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $38,661,000. Avoro Capital Advisors LLC purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $28,599,000. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $10,848,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $49.33 on Wednesday. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The company has a market capitalization of $4.19 billion, a PE ratio of -18.14 and a beta of 1.70. The company has a 50 day moving average price of $56.97 and a 200-day moving average price of $63.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. The business’s revenue was down 99.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.98) EPS. On average, analysts forecast that CRISPR Therapeutics will post -5.52 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.